Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing
and commercializing transformative inhalation therapies for the world’s most debilitating diseases
Founded in 2015 by a team of passionate and experienced experts in inhalation therapy, our vision is to
harness the potential of inhalation therapy to improve and transform the lives of
people living with the diseases for which more treatment options are needed.
Selected as a quasi-unicorn enterprise in Hangzhou in 2021
Successfully identified as the R&D center of science and technology enterprises in Yuhang District, Hangzhou in 2019
Successfully recognized as a high-tech enterprise in Hangzhou in 2018
Won the "China's Top 80 Healthcare Innovation Enterprises" in 2020
Recognized as a small and medium-sized science and technology enterprise
Selected as a quasi-unicorn enterprise in Hangzhou in 2020
Won the third place in the Zhejiang Province Division of the National Innovation and Entrepreneurship Competition and the National Outstanding Award in 2019
Won the title of Hangzhou "Young Eagle Plan" Enterprise in 2016
Listed as the first top 60 recipients for "Kunpeng Plan" in future technology city in Hangzhou in 2018
